Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinpoint Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,733,061

426 payments

Through program year 2025, Clinpoint Trials LLC is reported as receiving $1,733,061 in research payments, across 426 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $157,448 58
2024 Research $319,041 86
2023 Research $215,385 57
2022 Research $211,236 63
2021 Research $140,694 40
2020 Research $195,316 64
2019 Research $493,941 58

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $735,437 148 payments
  2. AbbVie, Inc. $559,082 174 payments
  3. Eli Lilly and Company $214,187 29 payments
  4. GlaxoSmithKline, LLC. $112,857 40 payments
  5. Teva Pharmaceuticals USA, Inc. $32,162 17 payments
  6. Gilead Sciences, Inc. $27,092 5 payments
  7. Genentech, Inc. $19,655 2 payments
  8. Moderna TX, Inc. $13,637 6 payments
  9. Pfizer Inc. $11,171 3 payments
  10. Ardelyx, Inc. $7,782 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $298,619 27 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $129,357 28 payments
  3. A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine $91,188 20 payments
  4. Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $81,216 15 payments
  5. Pediatric Options for Migraine Relief A Randomized, Double Blind, Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $74,902 9 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $74,694 7 payments
  7. Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $67,217 31 payments
  8. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $61,035 15 payments
  9. A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation $60,986 20 payments
  10. Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $57,550 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record